161 related articles for article (PubMed ID: 36931661)
1. Serpin B9 controls tumor cell killing by CAR T cells.
Kimman T; Slomp A; Martens A; Grabherr S; Li S; van Diest E; Meeldijk J; Kuball J; Minnema MC; Eldering E; Bovenschen N; Sebestyén Z; Peperzak V
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36931661
[TBL] [Abstract][Full Text] [Related]
2. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
3. Overview of serpin B9 and its roles in cancer (Review).
Wang WJ; Wang J; Ouyang C; Chen C; Xu XF; Ye XQ
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34278491
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
5. Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.
Tang L; Zhang H; Zhou F; Wei Q; Du M; Wu J; Li C; Luo W; Zhou J; Wang X; Chen Z; Zhang Y; Huang Z; Wu Z; Wen Y; Jiang H; Liao D; Kou H; Xiong W; Mei H; Hu Y
Cancer Commun (Lond); 2024 Mar; 44(3):408-432. PubMed ID: 38407943
[TBL] [Abstract][Full Text] [Related]
6. B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.
Hagn M; Blackwell SE; Beyer T; Ebel V; Fabricius D; Lindner S; Stilgenbauer S; Simmet T; Tam C; Neeson P; Trapani JA; Schrezenmeier H; Weiner GJ; Jahrsdörfer B
Int Immunol; 2014 Jul; 26(7):383-95. PubMed ID: 24497611
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.
Wang L; Zhang Y; Anderson E; Lamble A; Orentas RJ
Front Immunol; 2022; 13():825364. PubMed ID: 35222407
[TBL] [Abstract][Full Text] [Related]
10. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition.
Montalvo MJ; Bandey IN; Rezvan A; Wu KL; Saeedi A; Kulkarni R; Li Y; An X; Sefat KMSR; Varadarajan N
Cell Death Dis; 2024 Feb; 15(2):109. PubMed ID: 38307835
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
Front Immunol; 2021; 12():782448. PubMed ID: 34868059
[TBL] [Abstract][Full Text] [Related]
12. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
13. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S
J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669
[TBL] [Abstract][Full Text] [Related]
14. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes.
Sun J; Bird CH; Sutton V; McDonald L; Coughlin PB; De Jong TA; Trapani JA; Bird PI
J Biol Chem; 1996 Nov; 271(44):27802-9. PubMed ID: 8910377
[TBL] [Abstract][Full Text] [Related]
15. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
16. Stably transfected antisense granzyme B and perforin constructs inhibit human granule-mediated lytic ability.
Bochan MR; Goebel WS; Brahmi Z
Cell Immunol; 1995 Sep; 164(2):234-9. PubMed ID: 7656332
[TBL] [Abstract][Full Text] [Related]
17. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
[TBL] [Abstract][Full Text] [Related]
18. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
19. Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.
Viswanathan K; Bot I; Liu L; Dai E; Turner PC; Togonu-Bickersteth B; Richardson J; Davids JA; Williams JM; Bartee MY; Chen H; van Berkel TJ; Biessen EA; Moyer RW; Lucas AR
PLoS One; 2012; 7(9):e44694. PubMed ID: 23049756
[TBL] [Abstract][Full Text] [Related]
20. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]